Former FDA Chiefs Califf, Gottlieb, Sharpless Critique HHS Oversight in Rare Public Unity

The commissioners described fragmented decision-making at HHS that has delayed guidance on drug approvals and device safety, citing internal process breakdowns rather than external political pressure. Their remarks drew on experiences across administrations, noting that direct commissioner-to-secretary reporting lines have weakened since 2021 reorganization efforts. Data from FDA annual reports show a 12 percent rise in review times for priority drugs between 2023 and 2025, though causation remains unproven.

Public trust metrics from the Pew Research Center indicate a 9-point drop in confidence in federal health agencies since 2022, correlating with visible leadership turnover. This pattern echoes prior episodes of agency friction during the 2017-2019 opioid guidance revisions, where commissioner statements similarly preceded congressional oversight hearings.

Analysts expect the comments to accelerate calls for statutory protections on FDA autonomy ahead of 2027 appropriations debates. A House hearing scheduled for December could test whether these critiques translate into legislative language.

Next steps hinge on whether incoming leadership signals willingness to restore direct reporting channels; absent such moves, commissioners may issue a joint white paper by Q1 2027.